ARTELO BIOSCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $7.21M
- P/E (TTM)
- –
- Dividend yield
- –
About Artelo Biosciences
Pharmaceutical Preparations, SIC 2834
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system. The company's pipeline includes ART27.13, a synthetic dual cannabinoid receptor agonist in clinical trials for cancer-related anorexia; ART26.12, an inhibitor of fatty acid binding protein 5 being evaluated for chemotherapy-induced peripheral neuropathy, cancer, and pain; and ART12.11, a proprietary cannabidiol cocrystal composition for anxiety disorders and depression. Because its drug candidates remain in clinical and preclinical stages, the company currently has no commercial sales, but aims to make prescription treatments available to patients following regulatory authorizations.
The company engages in research and development activities across multiple countries, collaborating with academic institutions and clinical research organizations in the United States, Canada, Ireland, China, and the United Kingdom. Its Phase 2a clinical study operates across eighteen clinical sites located in five countries. Artelo Biosciences maintains its headquarters in the County of San Diego, California.
Summary of the business section of Artelo Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ARTELO BIOSCIENCES, INC.
- Founded
- 2011
- Headquarters
- Solana Beach, CA
- Address
- 505 Lomas Santa Fe, Suite 160 92075
- Phone
- (858) 925-7049
- Website
- artelobio.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- ARTL
- Exchange
- Nasdaq
- IPO date
- Jun 21, 2019
- Shares outstanding
- 5M, Aug 11, 2026
- Public float
- $9.29M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-9 reverse, Aug 31, 2026; 1-for-3 reverse, Mar 10, 2026; 1-for-6 reverse, Aug 13, 2025; 1-for-6 reverse, Jun 13, 2025; 1-for-15 reverse, Aug 10, 2022; 1-for-8 reverse, Jul 15, 2019
- SEC CIK
- 1621221
- CUSIP
- 04301G607
- ISIN
- US04301G6070
- EIN
- 33-1220924
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gregory D. Gorgas | Pres, CEO, CFO, Treas & Secr, Director | 273,076 |
| Mark Edward Spring | Chief Financial Officer | – |
| Tamara A. Favorito | Director | – |
| Robert Martin Emanuele | Director | 12,500 |
| Steven Kelly | Director | 12,500 |
| Douglas Blayney | Director | 12,500 |
| Gregory Reyes | Director | – |
| Connie Matsui | Director | 56,667 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Gergory Gorgas | $1.21M | $883.19K | $41.67K | $7070 | – |
| FY2024 Gergory Gorgas | $1.06M | $879.83K | $0 | $36680 | – |
| FY2023 Gergory Gorgas | $994.10K | $664.63K | $0 | $48440 | – |
| FY2022 Mr. Gorgas | $654.83K | -$153.81K | $0 | $37120 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“The Company currently has five employees and utilizes approximately twenty-five consultants and contractors.”
Corporate history
Events identified from SEC filings